Abstract Purpose: Multiple interventions have been tested in acute respiratory distress syndrome (ARDS). We examined the entire agenda of published randomized controlled trials (RCTs) in ARDS that reported on mortality and of respective meta-analyses. Methods: We searched PubMed, the Cochrane Library, and Web of Knowledge until July 2013. We included RCTs in ARDS published in English. We excluded trials of newborns and children; and those on short-term interventions, ARDS prevention, or post-traumatic lung injury. We also reviewed all meta-analyses of RCTs in this field that addressed mortality. Treatment modalities were grouped in five categories: mechanical ventilation strategies and respiratory care, enteral or parenteral therapies, inhaled/intratracheal medications, nutritional support, and hemodynamic monitoring. Results: We identified 159 published RCTs of which 93 had overall mortality reported (n = 20,671 patients)-44 trials (14,426 patients) reported mortality as a primary outcome. A statistically significant survival benefit was observed in eight trials (seven interventions) and two trials reported an adverse effect on survival. Among RCTs with more than 50 deaths in at least one treatment arm (n = 21), two showed a statistically significant mortality benefit of the intervention (lower tidal volumes and prone positioning), one showed a statistically significant mortality benefit only in adjusted analyses (cisatracurium), and one (high-frequency oscillatory ventilation) showed a significant detrimental effect. Across 29 metaanalyses, the most consistent evidence was seen for low tidal volumes and prone positioning in severe ARDS. Conclusions: There is limited supportive evidence that specific interventions can decrease mortality in ARDS. While low tidal volumes and prone positioning in severe ARDS seem effective, most sporadic findings of interventions suggesting reduced mortality are not corroborated consistently in large-scale evidence including meta-analyses.
Introduction
The acute respiratory distress syndrome (ARDS) [1] carries high mortality (typically 27-45 %) [2, 3] . Patients typically die from the underlying cause of ARDS, sepsis, and/or multiorgan failure [4] [5] [6] . Currently there are no specific therapies for ARDS that are widely and unequivocally recommended, except for mechanical ventilation (MV) with low tidal volumes [7] . However, there are numerous trials on ARDS and some of them have occasionally reported significant benefits. By examining single trials in isolation it is difficult to judge which results reflect genuine benefits of the tested interventions and which might be due to diverse biases [8] . Furthermore, several trials in which the intervention showed a potential beneficial effect were stopped early, which can inflate estimates of treatment effects [9] . To understand which treatments can reduce mortality in ARDS, one should examine the entire agenda of published trials for this condition, instead of focusing on one intervention at a time [10] .
Here, we aimed to review all the agenda of published randomized controlled trials (RCTs) on ARDS using an umbrella review of the evidence. In an umbrella review, the data from clinical trials on diverse interventions for a particular disease are juxtaposed, facilitating a bird's eye view analysis of the strengths, weaknesses, and biases of this literature [10, 11] . Here, we analyzed the results of RCTs of treatments for ARDS that reported on mortality outcomes. We also systematically overviewed the results of all the respective meta-analyses in this field reporting mortality outcomes. We aimed to map whether any interventions have robust evidence that they can curtail mortality for this syndrome.
Methods

Eligibility criteria for randomized controlled trials
We considered all published RCTs involving therapies for the treatment of ARDS. Trials have been performed over many decades and definitions of ARDS have evolved over time. We tried to be all-encompassing and therefore we considered all definitions of ARDS [1, 12] . RCTs in patients with ARDS published in English were retained if they compared an intervention against placebo or another intervention, regardless of whether there were also common ''backbone'' interventions (treatments that were provided to all study patients, irrespective of the treatment arm). We excluded trials performed in newborns and children because causes and management options for ARDS are generally different from those in adults. In addition, we excluded trials that analyzed a subset of patients from a larger study, tested short-term interventions lasting minutes (e.g., different modes of suctioning, single recruitment maneuver), focused on ARDS prevention, or evaluated subjects with post-traumatic or inhalation injury. We also included all metaanalyses of RCTs in ARDS that had mortality as an outcome.
Search strategy
We searched PubMed, the Cochrane library, and Web of Knowledge with last update on the 25 July 2013. We retrieved articles published in the English language without limits on publication year and perused reference lists of related papers, meta-analysis, and review articles for additional pertinent citations. We used the following search algorithm for PubMed search of RCTs: (((((adult respiratory distress syndrome) OR (hypoxemic respiratory failure) OR (acute lung injury)) AND (''random*'' OR ''controlled trial'' OR ''randomized controlled trial'' OR ''placebo'' OR ''double-blind'')) AND Humans [Mesh] AND English [lang])) NOT infant [MeSH Terms]. Furthermore, we systematically searched PubMed for relevant meta-analyses that included mortality as one of the outcomes. When more than one meta-analysis had tested the same (or overlapping) interventions, we kept all of them, so as to juxtapose their results and see whether they were consistent. However, we did not include the older version of two meta-analyses that were published by the very same authors on the same intervention with 2-3 years difference between the old and newer versions.
We employed a similar strategy to search the Web of Knowledge for RCTs excluding Medline (Topic = (((adult respiratory distress syndrome) OR (hypoxemic respiratory failure) OR (acute NEAR/3 lung NEAR/3 injury)) AND (''random*'' OR ''controlled trial'' OR ''randomized controlled trial'' OR ''placebo'' OR ''double-blind'')) NOT Topic = (infant*) NOT Topic = ((rat OR mouse OR mice OR dog OR animal)) Refined by:
[excluding] Databases = (MEDLINE) AND Languages = (ENGLISH) Timespan = All years.). Furthermore we queried the Cochrane Central Registry of Controlled Trials with ((adult respiratory distress syndrome) OR (hypoxemic respiratory failure) OR (acute lung injury)), Limit to ''Trials'' and ''meta-analysis''.
Data extraction
Two investigators (J. Z. and A. R. T) screened abstracts and articles and identified those that met inclusion/ exclusion criteria. When we identified overlapping reports on the same trial, we analyzed data from the most complete report. We reviewed the full text of all articles selected by the reviewers. Two investigators independently extracted data. Differences were resolved by consensus (all authors). For RCTs, we extracted data regarding the first author's name, publication year, intervention administered, number of participants per treatment arm, and primary outcome. We recorded mortality data, calculated from 2 9 2 tables of deaths per arm the respective odds ratios and risk ratios, and recorded any reported hazard ratios (adjusted and unadjusted) for time-to-event analyses of mortality. We flagged statistically significant differences in mortality (defined as p \ 0.05 or 95 % CI of a relative risk metric entirely on one side of 1.00).
For meta-analyses we collected the total number of participants and deaths in each arm, follow-up time, risk ratio and odds ratio with 95 % CI, model used for analysis (fixed or random), and heterogeneity index I 2 .
Overall design of the umbrella review Interventions were grouped in five categories: MV strategies and respiratory care, enteral or parenteral therapies, inhaled/intratracheal medications, nutritional support, and hemodynamic monitoring. Specific interventions tested are presented in Table 1 in the electronic supplementary  material (ESM). Although death is a major ARDS outcome, not all trials reported on mortality. Perhaps some trials did not consider mortality, e.g., if the trials were very grossly underpowered for mortality assessment; or selectively did not report death outcomes. Therefore, we recorded in how many trial reports information on mortality was mentioned at all. We then particularly focused on RCTs that claimed to have overall mortality as a primary outcome or also provided mortality data in the text. We investigated whether any claims were made by the authors that any apparent survival benefits of a particular intervention pertained to the entire or a subset of the study population. Whenever a survival benefit was claimed for a particular subgroup, we determined whether these analyses were defined a priori or post hoc.
In addition, we examined all the available published meta-analyses in ARDS patients on the respective interventions, and compared their results with those of selected trials and against each other, whenever two or more meta-analyses had evaluated the same intervention.
Analyses
We calculated odds and risk ratios with their respective 95 % CIs using MedCalc version 12.7 (Ostend, Belgium). When reported, we also presented hazard ratios and 95 % CIs, presenting whatever adjustments may have been used by the primary authors.
Mortality outcomes may be assessed at different times of follow-up in the same trial. Whenever treatment effects were provided at different times of follow-up for the same trial, we selected the one that was considered to represent the primary analysis according to the authors; if this was unclear, we selected the longest follow-up data. However, we also recorded in a separate table mortality treatment effect estimates (calculated odds ratios and risk ratios) and their 95 % CIs for all time points provided in the manuscript, so as to assess whether these differed for the same trial (e.g., statistically significant only for some, but not all time points). Methodological aspects of the quality of the trials are shown in the ESM. Additional aspects of quality, such as the quality of care and the extent of standardization of the control and active interventions, may be important, but are typically hard to arbitrate based on published information.
Results
Eligible ARDS trials
We identified 159 published RCTs that tested a variety of interventions in patients with ARDS ( Fig. 1 ; Tables 1 and  2 in the ESM). We grouped the interventions tested in five groups as shown in Table 1 and Tables 1 and 2 in the ESM. Of all selected trials, 93 had overall mortality reported and included 20,671 randomized patients (Table 2) [S1-S93]. The other 66 trials with a total of 1,398 randomized patients did not report mortality data and the median (IQR, interquartile range) of patients per study was 18 (12-26) with a range of 5-72 subjects. Of the studies without mortality data, the follow-up ranged from 2 h up to 7 days and 35 (53 %) had crossover design. The outcomes in these studies were changes in the oxygenation, hemodynamics, respiratory mechanics, or inflammatory markers (Tables 3-7 in the ESM).
Of the 93 trials (S1-S93) analyzed in more depth [n = 20,671 randomized patients with a median (IQR) 99 (49-293) subjects per study (range 15-1,001)], 44 included mortality as a primary outcome with 14,426 randomized patients; another 49 trials (n = 6,245) reported death as a specified secondary outcome (31 trials, n = 5,231) or simply as additional information in the manuscript (18 trials, n = 1,014). Mortality was reported during the ICU or hospital stay or during follow-up ranging from 28 days (minimum) to 6 months (maximum) ( Table 2 ). A total of 32 studies were prematurely terminated [documentation of beneficial effect considered unlikely (n = 18), perceived overwhelming evidence for benefit (n = 5), perceived documentation of a detrimental effect (n = 3), slow recruitment (n = 6)].
Of the 93 trials, 21 had at least 50 deaths in one study arm ( Fig. 2 ; Table 8 in the ESM) (20 had at least 50 deaths in both study arms).
Differences in mortality
There was a statistical significant difference in mortality favoring the intervention in eight studies (prone positioning, two studies [20, 34] ; cisatracurium [24] ; high positive end-expiratory pressure (PEEP) and low tidal volume [35] ; lower tidal volume, two studies [13, 36] ; pressure control ventilation [37] ; and prolonged methylprednisolone [38] ). Only six [13, 20, [35] [36] [37] [38] of these eight trials yielded a statistically significant difference using unadjusted metrics; the other two trials showed a statistically significant survival benefit only on adjusted HR (prone positioning [34] and cisatracurium [24] ), but the difference was non-significant in unadjusted analyses. Two trials actually reported a statistically significant adverse effect on survival [high-frequency oscillatory ventilation (HFOV) and intravenous oxothiazolidine].
Of the studies that included more than 50 deaths in at least one treatment arm ( Fig. 2 ; Table 8 in the ESM), only three showed a mortality benefit of the intervention (lower tidal volumes [13] , prone positioning [20] , cisatracurium [24] ), and one of them (cisatracurium [24] ) did so only in adjusted analyses, as described above. One trial (HFOV [17] ) suggested a detrimental effect of the active treatment and 17 showed no statistically significant difference between study arms (Fig. 1) .
A total of 23 trials presented mortality outcome data on two or more different time points. In three trials one or more analyses found a non-significant difference, but analysis with different follow-up showed a statistically significant benefit (pressure-controlled ventilation [37] , primary analysis; inflammation-modulating diet [39] , secondary analysis) or a statistically significant harm (sivelestat [33] , secondary analysis) regarding survival. In 22 of the 23 trials, the relative risk results for mortality amply overlapped the 95 % CIs, while in the case of inflammation-modulating diet [39] the large benefit at 28 days was incongruent with the results at 14 days (primary analysis) and 90 days.
Meta-analyses
Of 147 screened citations (PubMed 91, Cochrane 56), 29 meta-analyses were selected (Table 3) [3, . These meta-analyses tested a variety of interventions including low tidal volumes (n = 3) [47, 50, 59] , prone positioning (n = 5) [3, 40, 45, 52, 63], higher PEEP (n = 6) [46, 48, 55, 57, 59, 60] , HFOV (n = 1) [61] , non-invasive ventilation (n = 1) [44] , nitric oxide (n = 2) [41, 42] , exogenous surfactant (n = 3) [49, 54, 65] , corticosteroids (n = 4) [43, 53, 56, 62] , cisatracurium (n = 1) [64] , inflammation-modulating diet (n = 2) [58, 67] , inhaled b2 agonists (n = 1) [66] , and sivelestat (n = 1) [51] ; one meta-analysis tested two interventions (low tidal volume and higher PEEP) [59] . Interventions that statistically significantly reduced mortality based on the provided summary effects on the overall population included low tidal volume ventilation (in three out three meta-analyses) [47, 50, 59] , HFOV (in the single meta-analysis performed) [61] , high PEEP (in three out of six metaanalyses) [46, 55, 57] , cisatracurium (in the single metaanalysis performed) [64] , and inflammation-modulating diet (in the two meta-analyses performed) [58, 67] . Meta-analyses that have assessed low tidal volume have consistently suggested statistically significant mortality benefits [47, 50, 59] . However, upper 95 % CIs are close to 1.00 and one meta-analysis found a benefit only in a subgroup that used a comparator of higher tidal volumes and plateau pressures.
One meta-analysis of HFOV showed a 23 % significant reduction in the relative risk [61] ; however, the two largest trials (published after this meta-analysis, each of them larger than the meta-analysis in sample size) [17, 32] have found either no benefit (risk ratio 1.02) [32] or a significantly increased risk of death (risk ratio 1.33) [17] .
The six existing meta-analyses of high PEEP [46, 48, 55, 57, 59, 60] yield similar summary treatment effects with 95 % CIs close to 1.00. One meta-analysis [46] found a favorable effect of high PEEP in ICU but not hospital mortality; nevertheless, the results are consistently nonsignificant when the different levels of PEEP are compared in patients ventilated with low tidal volumes.
A meta-analysis [64] of intravenous cisatracurium infusion showed a mortality benefit at different time points (ICU, hospital, and 28 days); however, it included three studies of markedly different size performed by the same groups of investigators in France.
In addition, two meta-analyses using the same three studies [58, 67] found a reduction in mortality in patients receiving an inflammation-modulating diet; however, this result applies to data on 28-day mortality and is driven by the study discussed above [39] that had a favorable estimate at 28 days, but showed a trend for increased mortality at 14 days and no benefit at 90 days.
Eight of the 29 meta-analyses made claims for the presence of a survival benefit in subsets of patients with greater background disease severity and/or hypoxemia (n = 6) [3, 40, 45, 46, 52, 55] , with different doses (n = 1) [53] , or different settings for the control/background intervention (n = 1) [50] (Table 3 ). The most consistent observation seemed to be that prone positioning reduced the hospital mortality in the subgroup of patients with more severe hypoxemia, but not overall. This observation was made by at least three of the five respective meta-analyses, and it was validated also in a subsequent RCT [68] published after these five meta-analyses of prone positioning showing a 51 % relative risk reduction (58 % in adjusted analysis) in a study population with severe ARDS.
Discussion
Despite 159 RCTs and 29 meta-analyses on ARDS treatment, and sporadic significant findings in single Based on statistical significance (crude or adjusted ratios) a positive sign represents a beneficial effect, a negative sign a deleterious effect and an empty box the lack of difference in survival between the study groups papers, the available evidence seems to consistently support a reduction in overall mortality with low tidal volume ventilation and also with prone positioning among patients with severe ARDS. These two interventions may really be the only ones that can be currently recommended for routine clinical use with rigorous support. Beyond these two interventions, sporadic claims of mortality benefits seem to be spurious and reflect chance findings or selective analyses, as has been seen also in other fields [69, 70] . This may apply to cisatracurium [24, 64] , HFOV [61, 71] , high PEEP [35, 46, 55, 57, 60] , pressure control ventilation [37] , corticosteroids [38, 53, 72] , and inflammation-modulating diet [39, 58, 67] . As a result of the limited number of patients, often we cannot exclude modest benefits with certainty. However, when large trials have been performed, they have shown no benefit, or even harm, as in the case of HFOV. Conducting additional definitive large trials may be warranted to settle some of the other unclear claims or before universally adopting results of a single large randomized control trial. An alternative approach would be the inclusion of fewer patients who are at higher risk for the outcome of interest.
Even for the two best documented interventions that apparently decrease mortality in ARDS, the exact range of indications for their application is not fully settled. MV with low tidal volume is now a well-established practice in the treatment of ARDS as higher tidal volumes can overstretch the alveoli leading to inflammation and lung injury [73] . It remains unclear, however, whether this intervention provides a survival benefit when compared with relatively higher tidal volumes that limit the airway pressures [50] . Interestingly, this ''lung-protective'' ventilation modality is likely to be beneficial even among patients without ARDS [74] . As for prone ventilation, it has taken a long time (the first RCT was published in 2001) to decipher how to apply it. Five meta-analyses [3, 40, 45, 52, 63] published between 2008 and 2011 found very similar, non-significant overall effects, but at least three of them identified a significant benefit for mortality in patients with more severe ARDS [3, 40, 52] . Then, a recent large study showed a 28-day survival improvement in those patients that received prone positioning [20] . Low tidal volumes and prone positioning may even need to be applied concurrently. According to a meta-analysis published after the end of our search, benefits from prone position have been demonstrated only in trials that also use low tidal volumes [75] .
Among other interventions, neuromuscular blockers and high PEEP have interesting tentative signals of benefit. Neuromuscular blockers may improve oxygenation and decrease inflammation [76, 77] . Cisatracurium has shown a 90-day adjusted survival benefit when compared to placebo [24] , but not in an unadjusted analysis. Treatment effects that are analysis-dependent are tenuous [78] . A recent meta-analysis [64] also concludes in favor of the short-term infusion of cisatracurium as this treatment may reduce hospital mortality and barotraumas without significant side effects. However, the data come from the same group of investigators and the mortality Fig. 2 Calculated unadjusted risk ratios for mortality in randomized trials in ARDS that had more than 50 deaths in at least one arm. When multiple follow-up durations were provided we focused on the follow-up that defined the primary mortality outcome. In the event that this was not available we considered the time point of the secondary outcome and if none was available the longer follow-up time. CVP central venous pressure, HFOV high-frequency oscillatory ventilation, PAOP pulmonary artery occlusion pressure, PEEP positive end-expiratory pressure, PGE1 prostaglandin E1 Table 3 Meta-analyses of randomized trials that evaluate mortality in ARDS Author, reference [46, 48, 55, 57, 59, 60] . Perhaps this intervention might be beneficial in patients with severe ARDS, as in the case of prone ventilation, but this hypothesis needs validation in a large trial. Higher levels of PEEP may increase the proportion of aerated lung at end-expiration, preventing lung injury, improving oxygenation, and permitting a lower inspiratory fraction of O 2 , which in turn limits pulmonary oxygen toxicity [79, 80] .
The field of ARDS therapeutics has had a large number of RCTs and meta-analyses performed to date. For some topics, there have been multiple (up to six) meta-analyses on the same intervention. While some independent validation of meta-analyses is useful, redundancy could be avoided [81] . At this stage, it is unlikely that priority should be given to performing more small trials and more meta-analyses of single interventions. Besides the 159 published RCTs and 29 metaanalyses that we identified, in preliminary searches we identified another 117 unpublished trials in clinicaltrials.gov (37 completed, 21 not yet recruiting, 43 recruiting, and 16 terminated) as of July 2013. Considering the possibility of additional trials that are neither published nor registered, the cumulative research agenda of ARDS may currently include over 300 RCTs. However, the large majority of them are small investigations where important outcomes such as mortality are difficult or impossible to investigate meaningfully. Results on mortality are likely to leave substantial uncertainty, even when they seem promising. Mortality benefits claimed in small trials very often represent spurious findings [82, 83] . There are few relatively large trials performed in the field, and the largest trial published to date has had 1,001 patients. We suggest that modestly large trials (e.g., with 500-1,000 patients) should become more common in the field. Such trials have been able to yield conclusive answers for tentative interventions, including both favorable (e.g., prone positioning) and unfavorable conclusions (e.g., HFOV). Nevertheless, of the 117 unpublished registered trials in clinicaltrials.gov, we found only nine that have an anticipated total sample size exceeding 500 (details in the ESM).
While modestly large trials would require by default multicenter collaborations and sufficient resources, successful precedents such as the PROSEVA trial on prone positioning [20] suggest that such a strategy is worth adopting more commonly. Small trials are likely more susceptible to selective reporting of analyses and outcomes, and results may become even more confusing with emphasis on subgroup analyses and other secondary explorations of the data [8, 84] . Given that ARDS is a common major problem affecting millions of patients annually, recruiting sufficient numbers of patients should be feasible. This applies also to situations where interventions are proposed for testing in specific subsets of patients where there may be biological or prior clinical evidence that they may be more effective.
Another important issue is the lack of standardization in the time period in which mortality in ARDS studies is reported. RCTs have used time points that include ICU, hospital, and 28-day up to 6-month mortality. This variability makes it difficult to compare the effects of different interventions. In many trials ICU and hospital mortalities were not reported, which are important outcome measures to assess the effect of ICU interventions. Most deaths in ARDS are not directly related to lung disease, but to extrapulmonary organ dysfunction [85] ; therefore, it is challenging to prove that interventions targeting the lung improve overall survival.
Our umbrella review has limitations. Firstly, we are limited by the amount and quality of available information in primary studies [11] . Moreover, it is difficult to generalize the results of these studies given the diverse inclusion/exclusion criteria and severity of disease [3, 20, 24, 86, 87] . Furthermore, there is inequality in the contribution of centers and lack of protocolized general care. Second, the vast majority of the evidence pertained to testing an intervention versus control management. Trials comparing head-to-head effective interventions are not available. Lower tidal volume was incorporated in clinical practice lately and until recently no other interventions have had strong evidence to support their use as standard controls. However, what constitutes standard management may change over time. Moreover, as some interventions start showing efficacy, head-to-head comparisons will become more important to perform [10] . One would need to design trials specifically addressing additive or synergistic effects of effective interventions, when these are used concomitantly [88] . Third, the results that we present focus on published information susceptible to reporting biases. Some of the spurious significant signals that we identified might have been reversed if additional unpublished data were available. However, obtaining unpublished data is notoriously difficult. This is one more reason why larger-scale collaboration to perform large multicenter trials is direly needed in the field. Issues of wider data sharing of the conducted trials, ideally at patient-level data, may need to be discussed as well [89] . Fourth, we focused specifically on mortality, while it is possible that some interventions may have beneficial effects on other outcomes, such as the duration of MV, without necessarily affecting mortality. Such interventions may still be useful, but here we focused on the most important outcome that matters in this setting.
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